RxDoctor Payments DataLook up a doctor →

Amy Illescas, MD

Internal Medicine · Hoover, ALNPI 1346269123

Payments from drug & device makers

$19,952in general payments, 2019–2025

Across 1,369 payments — averaging $14.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$4K
  • AbbVie$2K
  • Lilly USA, LLC$2K
  • Pfizer$1K
  • Dexcom, Inc.$1K
  • Amgen$1K
  • plus $8K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk277$3,944
AbbVie(2 entities)212$2,423
Lilly USA, LLC156$1,973
Pfizer83$1,142
Dexcom, Inc.61$1,066
Amgen72$1,039
Bayer49$901
Takeda Pharmaceuticals U.S.A., Inc.49$760
AstraZeneca(2 entities)25$606
Exact Sciences27$411
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC28$400
Antares Pharma, Inc.21$383
Intra-sana Laboratories10$277
Merck23$276
Ironwood Pharmaceuticals, Inc17$256
Boehringer Ingelheim16$253
Biohaven Pharmaceutical Holding Company Ltd.16$247
Otsuka America Pharmaceutical, Inc.11$193
Vivus LLC13$191
Upsher-smith Laboratories LLC12$187
Neos Therapeutics, LP13$182
Johnson & Johnson12$172
Astellas Pharma US Inc9$151
Phathom Pharmaceuticals, Inc.11$148
Amarin Pharma, Inc.10$145
Ardelyx, Inc.6$140
Lundbeck LLC8$123
Xeris Pharmaceuticals, Inc.5$99
Shield Therapeutics Inc6$97
Halozyme Inc4$94
GSK6$92
Esperion Therapeutics, Inc.6$90
Abbott5$83
Corium, LLC4$69
Hologic Sales And Service, LLC4$69
Supernus Pharmaceuticals, Inc.4$65
Genentech USA, Inc.5$63
Idorsia Pharmaceuticals US Inc4$63
Nabriva Therapeutics, PLC4$63
Biohaven Pharmaceuticals, Inc.4$58
Almatica Pharma LLC3$57
Eisai Inc.4$57
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)3$50
BETA Bionics, Inc.2$46
Sanofi-aventis U.S. LLC2$41
Tolmar, Inc.3$41
Verity Pharmaceuticals Inc.2$39
Neurocrine Biosciences, Inc.2$38
Nalpropion Pharmaceuticals LLC3$36
IBSA Pharma Inc.2$34
Collegium Pharmaceutical, Inc.2$30
Axsome Therapeutics, Inc.2$30
Currax Pharmaceuticals LLC2$29
Assertio Therapeutics, Inc.2$27
Boston Scientific1$27
Regeneron Healthcare Solutions, Inc.1$24
Mannkind Corporation2$24
Jazz Pharmaceuticals Inc.2$24
Arbor Pharmaceuticals, Inc.2$23
Inari Medical, Inc.1$21

How this compares

$19,952 in reported general payments places this provider in the 95th percentile of 1,533 internal medicine providers in Alabama.

See all internal medicine providers in Alabama →

Medicare billing

Part B allowed, 2024
$215,196
Medicare patients
362
Services billed
14,706

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other internal medicine in Hoover

See the full list for Alabama →

Where these figures come from

Is this you, or does something look wrong? →